Infectious diseases

Ebola: the essential facts

Pharmacists are ideally placed to help educate the public during the current outbreak of Ebola virus disease.

Ebola facilities at the Royal Free Hospital in London

Source: Leon Neal / AFP / Getty Images

Ebola is treated in the UK at the Royal Free Hospital’s high level isolation unit, which uses controlled ventilation tents around patients’ beds to contain any infection

The current Ebola outbreak is the most widespread ever recorded. Since it began in Guinea in December 2013, it has spread to Liberia, Nigeria and Sierra Leone. As of 26 August 2014, there were 3,069 cases and 1,552 deaths[1].

The first reported outbreak of Ebola virus disease (EVD) occurred in 1976 in the Democratic Republic of the Congo (then Zaire). The 2014 outbreak is by far the biggest in terms of numbers of people affected and geographical spread. It is also the first time that a large urban area (Monrovia, the capital of Liberia) has been affected; previous outbreaks have tended to occur in relatively remote areas, making it easier to impose quarantine procedures. There are now fears that infected individuals could travel outside of Africa.

On 8 August 2014, the World Health Organization (WHO) declared the outbreak a Public Health Event of International Concern (PHEIC)1, meaning that it requires a co-ordinated international response. This has only happened twice before: for the swine flu pandemic in 2009 and the re-emergence of polio in 2014.

Pharmacists can make an important contribution in educating and reassuring the public about the risks of EVD, advising travellers planning on visiting an Ebola-endemic area and explaining what measures can be taken to minimise risk of infection.

What is Ebola?

EVD is a haemorrhagic disease. There are five known strains of Ebola virus; the current outbreak has been identified as Zaire ebollavirus. Ebola typically has a mortality rate of 50%–90%; the mortality rate of the current outbreak is 53%[1].

It is believed the virus resides in animal reservoirs. Outbreaks are thought to be caused by animal-to-human transmission after people consume or come into with species of animal harbouring the virus, including monkeys and bats.

The virus can be killed by a variety of disinfectants, including the hypochlorites used in household bleach and swimming pool chlorine. Disinfection of surfaces, therefore, is an important control measure. And as soap will kill the virus, hand washing with soap and water is another important measure. 

There are no specific treatments for EVD, although an experimental monoclonal antibody preparation has been used.

Transmission and symptoms

The Ebola virus is transmitted by direct with the body fluids of an infected patient or with a corpse of a person who has succumbed to disease. Viral entry is usually via mucus membranes, cuts or abrasions, and the virus can be transmitted from the dried body fluids of an infected individual on an object (e.g. bedsheets). Ebola can be sexually transmitted.

There is no risk of transmission during the incubation period, which usually lasts between 4–16 days following infection, with a range of 4–21 days. There is no transmission by air droplets (i.e. sneezing or coughing) and only a low risk of transmission during the early stages of the disease.

In the prodromal phase, it may present with non-specific flu-like symptoms including:

  • fever
  • diarrhoea
  • vomiting
  • muscle ache
  • sore throat
  • headache.

Pharmacists should always refer patients presenting with such symptoms who have returned from endemic areas to a GP urgently.  Although it is difficult to identify EVD based on early non-specific symptoms, the differential diagnosis includes other tropical diseases such as malaria or dengue fever.

Full symptoms of EVD can develop rapidly. Clinical signs may include:

  • gastrointestinal symptoms (e.g., vomiting, diarrhoea)
  • confusion
  • haemorrhage, including conjunctival injection (red eye)
  • rash
  • chest pain and shortness of breath.

The condition progresses to serious haemorrhagic complications and organ failure.

Infection risk

Family members or health workers caring for infected patients are at the greatest risk of infection. Those travelling to Ebola-endemic areas and not intending to have any with victims are at a very low risk. The WHO has not discouraged travellers from visiting countries reporting outbreaks and Public Health England advises the risk to tourists is low if precautions are followed[2].

Screening airline passengers at departure from affected areas or on arrival is not recommended, as measures such as thermal scanners are unlikely to identify cases. However, individual countries, such as Cameroon, have implemented such measures and imposed restrictions on entry.

There has never been a case of Ebola originating in or intially presenting in the UK. One Briton, who contracted EVD in Sierra Leone, was flown to the UK on 25 August 2014 to receive specialist care at the Royal Free Hospital’s high level isolation unit in London. 

Ebola treatment in the UK

Ebola is treated in the UK at the Royal Free Hospital’s high level isolation unit. The unit restricts access to only a specialist medical team and uses controlled ventilation tents around patients’ beds to contain any infection.

The unit has a dedicated laboratory and patient entrance, and includes autoclaves for destruction of medical waste and air filtration systems for effective quarantine.

Air passengers may be concerned about travelling on a plane with passengers with EVD. However, the chances of contracting the disease, even when sitting next to a person with an active infection, are very low. Nonetheless, airlines do have procedures if such a situation should arise, in which passengers at risk would be identified for monitoring after the flight for 21 days[3]

Travellers may be at increased risk of contracting EVD if they are admitted to a hospital where Ebola cases are being treated and quarantine arrangements are poor. For this reason, unnecessary travel to current hotspots such as Sierra Leone or Liberia should be avoided. Travellers visiting friends and relatives in affected areas are also at increased risk of EVD infection, as they may become involved in helping to care for victims.

Timeline of Ebola incidences

Timeline of Ebola incidences

Reported Ebola cases and deaths in major outbreaks by year. Source: WHO

Ebola prevention

A general risk assessment and risk management plan should be completed for anyone seeking travel health advice before entering an area where Ebola is endemic. 

The risk assessment should consider in particular the type of travel being undertaken (e.g., visiting friends and relatives, healthcare work), as well as the length of time being spent in the area.

The management plan should consist of steps to minimise the chance of contracting the disease, as well as addressing other risks and recommended travel advice, such as malaria chemoprophylaxis.

To minimise the risk of EVD infection when visiting an Ebola-endemic area travellers should be advised to3:

  • Avoid with symptomatic patients and their body fluids, deceased patients and their body fluids and wild animals (alive and dead);
  • Avoid bush meat in endemic areas (i.e., the meat of wild animals that could be a reservoir for the disease);
  • Wash hands regularly using soap or an alcohol-based hand sanitiser;
  • Consider avoiding unessential travel to affected countries;
  • Identify appropriate in-country healthcare resources in advance of travelling;
  • Check that medical insurance will cover repatriation in the event of infection. 

Larry Goodyer PhD MRPharmS FFTM RCPS(Glasg) FRGS is head of Leicester School of Pharmacy De Montfort University and director of Nomad Travel Store and Clinics.

 

  • This article was updated on 29 August 2014 to include the latest figures on reported Ebola cases and deaths.

Citation: The Salvadore DOI: 10.1211/PJ.2014.20066261

Readers' comments (1)

  • what are the control measures pharmascist and pharmacy employes should cnsider when deeling with query ebola patient specially crowded places like jedha saudia arabia during hag time

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00
  • Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

    £43.00
  • Pharmacy and the US Health Care System

    A complete source of current information about the US health care system. Includes concise reports on trends, regulations, policy and finances.

    £49.00
  • Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00
  • Pharmacy Registration Assessment Questions Package

    Pharmacy Registration Assessment Questions is a revision series featuring closed book and calculation questions. It can be used in conjunction with previous volumes or on its own to help you prepare for the GPHC exams.

    £80.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Supplementary images

  • Timeline of Ebola incidences
  • Ebola facilities at the Royal Free Hospital in London

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

средства для улучшения потенции

www.buysteroids.in.ua/inekczionnyie-anabolicheskie-steroidyi/testosteron/sp-propionate.html